Serum Biomarker Measurements of Endothelial Function and Oxidative Stress After Daily Dosing of Sildenafil in Type 2 Diabetic Men With Erectile Dysfunction

No AccessJournal of UrologyAdult Urology1 Jan 2009Serum Biomarker Measurements of Endothelial Function and Oxidative Stress After Daily Dosing of Sildenafil in Type 2 Diabetic Men With Erectile Dysfunction Arthur L. Burnett, Travis D. Strong, Bruce J. Trock, Liming Jin, Trinity J. Bivalacqua, and Biljana Musicki Arthur L. BurnettArthur L. Burnett Financial interest and/or other relationship with Pfizer, Inc., Lilly LLC and AMS. More articles by this author , Travis D. StrongTravis D. Strong More articles by this author , Bruce J. TrockBruce J. Trock Financial interest and/or other relationship with Bristol Myers Squibb. More articles by this author , Liming JinLiming Jin More articles by this author , Trinity J. BivalacquaTrinity J. Bivalacqua More articles by this author , and Biljana MusickiBiljana Musicki More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2008.09.005AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We investigated changes in serum biomarkers of vascular function after short-term, continuous sildenafil dosing in men with type 2 diabetes with erectile dysfunction. Materials and Methods: Men with erectile dysfunction associated with type 2 diabetes mellitus were randomized to receive continuous, daily sildenafil (50 mg for 1 week run-in and 100 mg for 3 weeks) (148), or placebo (144) for 4 weeks (phase I) and then sildenafil (25, 50 or 100 mg) on demand for 12 weeks (phase II). Blood draws at baseline and after phases I and II were analyzed for cyclic guanosine monophosphate (endothelial function marker), 8-isoprostane (oxidative stress marker), and interleukin-6 and interleukin-8 (inflammatory cytokines). Primary and secondary erectile function outcome variables were affirmative responses on Sexual Encounter Profile question 3 (ability to maintain erection sufficient for sexual intercourse) and Erection Hardness Score, respectively. Results: Serum cyclic guanosine monophosphate levels were increased in the sildenafil group relative to the placebo group at 4 (p <0.01) and 16 (p <0.05) weeks, correlating with affirmative responses to Sexual Encounter Profile question 3 at the 4-week interval only (p <0.05). Serum 8-isoprostane levels were decreased to a nonsignificant degree in the sildenafil group at 4 weeks with no further change at 16 weeks, whereas interleukin-6 and interleukin-8 levels were unchanged at either interval, and these levels were unassociated with erectile function outcomes. Conclusions: These data suggest that short-term, continuous sildenafil treatment causes systemic endothelial function to be enhanced and remain so for a duration after its discontinuation. However, they do not indicate any influence of this treatment on systemic oxidative stress or inflammation, or an effect on long-term erectile function improvement. References 1 : The epidemiology of sexual dysfunctions. J Sex Med2008; 5: 389. Google Scholar 2 : Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol2005; 96: 313. Google Scholar 3 : Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des2006; 12: 3467. Google Scholar 4 : The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nat Clin Pract Cardiovasc Med2007; 4: 263. Google Scholar 5 Pfizer Inc. Protocol No. A1481146: A multicenter, double-blind study to evaluate the effect of pre-treatment with a daily dose of Viagra (sildenafil citrate) on the PRN efficacy of Viagra in men with erectile dysfunction and Type 2 diabetes. Available at www.ClinicalStudyResults.org. Accessed February 4, 2008. Google Scholar 6 : Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res1999; 11: 319. Google Scholar 7 : Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care2003; 26: S5. Google Scholar 8 : Pharmacology. In: Nitric Oxide in Health and Disease. Cambridge: Cambridge University Press1997: 159. chapt 11. Google Scholar 9 : Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol1997; 17: 2309. Google Scholar 10 : Novel clinical markers of vascular wall inflammation. Circ Res2001; 89: 763. Google Scholar 11 : Sexual function assessment in the male: physiological and self-report measures. Int J Impot Res1998; 10: S59. Google Scholar 12 : Validation of the erection hardness score. J Sex Med2007; 4: 1626. Google Scholar 13 : Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med2008; 25: 138. Google Scholar 14 : Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opin Drug Metab Toxicol2007; 3: 451. Google Scholar 15 : Chronic administration of sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med2008; 25: 37. Google Scholar 16 : Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilation in type 2 diabetes. Diabetes Care2002; 25: 1336. Google Scholar 17 : Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol2005; 47: 214. Google Scholar 18 : Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil. Eur Urol2005; 48: 326. Google Scholar 19 : Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. Eur Urol2007; 51: 1411. Google Scholar 20 : Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol2006; 50: 351. Google Scholar 21 : Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric oxide synthase phosphorylation. Mol Pharmacol2005; 68: 226. Google Scholar 22 : Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol2005; 47: 87. Google Scholar 23 : Plasma levels of cyclic GMP and endothelin in postmenopausal women with unstable coronary artery disease. Scand J Clin Lab Invest1999; 59: 325. Google Scholar 24 : Endothelial function and dysfunction. Circulation2007; 115: 1285. Google Scholar Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland© 2009 by American Urological AssociationFiguresReferencesRelatedDetailsCited byChitaley K, Kupelian V, Subak L and Wessells H (2009) Diabetes, Obesity and Erectile Dysfunction: Field Overview and Research PrioritiesJournal of Urology, VOL. 182, NO. 6S, (S45-S50), Online publication date: 1-Dec-2009. Volume 181Issue 1January 2009Page: 245-251 Advertisement Copyright & Permissions© 2009 by American Urological AssociationKeywordsrehabilitationtype 5cyclic nucleotide phosphodiesterasescardiovascular diseasespenile erectionMetricsAuthor Information Arthur L. Burnett Financial interest and/or other relationship with Pfizer, Inc., Lilly LLC and AMS. More articles by this author Travis D. Strong More articles by this author Bruce J. Trock Financial interest and/or other relationship with Bristol Myers Squibb. More articles by this author Liming Jin More articles by this author Trinity J. Bivalacqua More articles by this author Biljana Musicki More articles by this author Expand All Advertisement PDF downloadLoading ...